Pepti, Checked but Not Graded: $99 Semaglutide and a Ladder That Renders Nowhere

Pepti (hellopepti.com) publishes the lowest semaglutide number of the seven telehealth sellers we checked in August 2026, and it publishes the strangest pricing artifact of the seven. Both of those sentences are load-bearing, and a board row that carried only the first would be selling a figure we are not certain of. So this company sits off the board with no WeighScore, no letter and no rank, and this page is the working file instead of a grade.

What the site charges, on the surface that renders

Injectable semaglutide is $99 a month and injectable tirzepatide is $199 a month, flat at every titration dose, with a one-time purchase option at $124 and $249 respectively.¹ The subscription is cancel-anytime with no minimum term and a pause of up to 90 days. Around those two sit oral semaglutide at $249, oral tirzepatide at $399, GLP-1 oral drops at $239, a GLP-1/GIP drop at $349, and two explicitly low-dose "longevity microdose" SKUs at $149 and $229.

A flat price at every dose is not a small claim. Dose-based step-ups are the mechanism by which a cheap-looking provider becomes an expensive one somewhere around month four, which is why our cost-value dimension normalizes to maintenance dose rather than starting dose — the reasoning is in how the WeighScore is calculated. If $99 holds at 2.4 mg, it is the cheapest rung of the seven companies in this pass — though graded providers on our own board publish month-to-month semaglutide below it, so this would not be the cheapest number on the site.

The unresolved finding

It may not hold. Pepti's production data carries a per-dose price ladder for both molecules that no part of the site renders and no component consumes: semaglutide at $299 for 0.25 mg, $349 for 0.5 mg, $399 for 1.0 mg and $449 for 2.4 mg; tirzepatide at $349, $399, $449 and $549 across its ladder. Meanwhile the company's own cost page states that all doses carry one flat monthly price of $99.

Those two things cannot both be true of the same product. One of them is dead code and one of them is the price. The rendered $99 is what the catalogue object carries, what the cost page says, and what several cross-sell surfaces repeat, so it is what we file — but the checkout endpoint answers only to POST requests, so we could not walk an intake to a real card screen and settle it. We are reporting this as unresolved rather than choosing the answer that reads better. A dormant ladder running three to four times the semaglutide headline is exactly the kind of thing that turns out to be live the week after somebody publishes the headline as fact.

Anyone shortlisting Pepti on price should get the maintenance-dose figure in writing before the first charge. That is good practice with any provider — it is the first item in our six-point checklist — and here it is the specific question that decides whether the offer is what it appears to be.

Where it ships, which is not fifty states

Four separate surfaces on the site — the shipping page, the state-availability page, the providers page and the homepage title — publish the same list of 36 states.² The terms of service say the services are available in 50. Four corroborating surfaces against one outlier line: we treat 36 as operative and would file it that way. At-home blood panels ship more broadly than the medication does.

When your card is charged

The how-it-works page says you pay nothing until a physician approves your treatment. The refund policy says payment is collected at checkout, before a licensed provider reviews your intake.³ Same company, opposite claims, and the refund policy is the operative document — so assume you are charged first and refunded on denial, which the policy puts at five to ten business days. Nothing is refundable once medication ships, and cancellation is not prorated.

That is the second internal contradiction on this site, and the pattern matters more than either instance. Contract terms carry only 8% of a WeighScore, but they are the dimension where a company's two surfaces disagreeing tells you something the marketing copy never will.

Oversight you can read, but not verify

Pepti names its prescribers properly: Dr. Gene Lee, MD, medical director, family medicine, licensed in 26 named states; Dr. Laeeq Butt, MD MBA, chief medical officer, internal medicine, licensed in 15. Both carry full bios with education and board certifications, which is more than most of this cohort offers.

Neither NPI is published, so neither name can be checked against the national provider registry — the difference between a bio and a verified prescriber. The dispensing pharmacy is never named at all; the site describes "independent FDA-registered 503A or 503B compounding pharmacies" and stops there. Our fulfillment dimension asks which pharmacy fills the vial, and that question has no answer here. Why it matters is in is compounded semaglutide legit and safe? The legal entity is pepti LLC at a Newark, Delaware address that is a registered-agent suite rather than an operating site.

The shelf around the GLP-1s

Pepti sells roughly 68 items — recovery peptides, nasal sprays, an anti-aging line, blood panels at $199. Some of that is ordinary: BPC-157 at $209 a month, sermorelin and tesamorelin at $189 each, NAD+ at $159 to $219 depending on route, a sleep peptide at $189.

Some of it is not, and we will not soft-pedal it. The catalogue includes retatrutide, melanotan II and IGF-1 LR3. Retatrutide has no FDA approval in any form, in any jurisdiction. This site does not treat any of those three as a recommendable option and never will, and a reader comparing GLP-1 programs should understand that a broad shelf is not automatically a feature. If your interest is the approved molecules and how they differ, semaglutide vs. tirzepatide is the comparison that is actually supported by trial data.

The regulatory screen

The FDA's live warning-letter index returned no company-column match for Pepti, for its legal entity, or for the compounding framework it names, in August 2026.⁴ The same pass returned a known February 2026 letter for an unrelated telehealth seller used as a positive control, so the zero is a real zero rather than a query that failed quietly. Worth noting what the neighbouring rows look like: a search on the company's own name-stem returns a long list of peptide sellers that do carry letters. Pepti is not among them.

What a grade would need

Two things, in order: a checkout screenshot at a maintenance dose that settles the $99-versus-$399 question, and an NPI for either named prescriber. With those, Pepti would be a serious entry on the cheapest GLP-1 ledger. Without them it stays here, in the working file, next to Trellis Vitality at $150 and Auren Rx at $199 — both of which publish a price we could reconcile with itself.